Latest NewsNov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases All Filter By: Year2024202320222021202020192018201720162015Aug 26, 2020HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 PatientsAug 17, 2020HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19Jul 3, 2020HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironmentJul 3, 2020Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environmentJul 3, 2020HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy< 1 … 9 10 11 12 13 … 17 >
